Merkel Year in Review: SPACE trial (JAMA 18) – opioids NOT superior to NSAIDs for function or pain in OA & back pain. #ACR18 @RheumNow pic.twitter.com/jQgc1eR67E
— ǝlʇʇıɥʍ ɯɐs (@samwhittle) October 21, 2018
US can be used to reliably identify structural and inflammatory changes in knee OA – often earlier or better than plain radiography. https://t.co/MSp2QlqSFP @RheumNow #ACR18 #2909
— Dr. Rachel Tate (@uptoTate) October 24, 2018
Dr. Cush
abstract 428
Significant Pain Reduction with Oral Methotrexate in Knee Osteoarthritis; Results from a Randomised Controlled Phase III Trial of Treatment Effectiveness —improved pain but not clinically meaningful
#ACR18 @Rheumnowhttps://t.co/S9wHaKjDLB— Suleman Bhana, MD (@DrBhana) October 24, 2018
Tanezumab sc (anti-nerve growth factor) interesting for OA knee and hip, but the added elective joint replacements without radiographic differences between groups remains unexplained. More safety data on the way #ACR18 ABSTL20 @RheumNow
— David Liew (@drdavidliew) October 23, 2018
We need to worry more about our SLE patients and their bone loss. #ACR18 @RheumNow. Abstract 2327. pic.twitter.com/vMDN2vtju8
— William Shergy (@WilliamShergy) October 23, 2018
LB abstract L03: Yazici et al. Phase 2b trial SM04690 infra-articular Wnt pathway Inhibitor for treatment of OA of the knee. Improvement in pain and function but not JSN. #ACR18 @RheumNow https://t.co/s8MjlqtIay
— Suleman Bhana, MD (@DrBhana) October 23, 2018